[1] Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis[J]. N Engl J Med, 2012, 366(9):799-807. DOI: 10.1056/NEJMoa1110557.
[2] Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis[J]. N Engl J Med, 2012, 366(9):787-98. DOI: 10.1056/NEJMoa1110556.
[3] Appeldoorn TYJ, Munnink THO, Morsink LM,et al. Pharmacokinetics and pharmacodynamics of ruxolitinib: a review[J]. Clin Pharmacokinet, 2023, 62(4):559-571. DOI: 10.1007/s40262-023-01225-7.
[4] Aslanis V, Umehara K, Huth F, et al. Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects[J]. Cancer Chemother Pharmacol, 2019, 84(4):749-757. DOI: 10.1007/s00280-019-03907-1.
[5] Aslanis V, Umehara K, Huth F, et al. Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects[J]. Cancer Chemother Pharmacol, 2019, 84(4):749-757. DOI: 10.1007/s00280-019-03907-1.
[6] Appeldoorn TYJ, Munnink THO, Morsink LM, et al. Pharmacokinetics and pharmacodynamics of ruxolitinib: a review[J]. Clin Pharmacokinet, 2023,62(4):559-571. DOI: 10.1007/s40262-023-01225-7.
[7] 中华医学会血液学分会白血病淋巴瘤学组. 原发性骨髓纤维化诊断与治疗中国指南(2019年版)[J]. 中华血液学杂志,2019,40(1):1-7. DOI:10.3760/cma.j.issn.0253-2727.2019.01.001.
[8] 严欣,徐泽锋,肖志坚. 芦可替尼治疗骨髓纤维化:不良反应及治疗失败对策研究[J]. 国际输血及血液学杂志,2019,42(5):429-434. DOI:10.3760/cma.j.issn.1673-419X.2019.05.011.
[9] Verstovsek S, Mesa RA, Livingston RA, et al. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety[J]. J Hematol Oncol, 2023, 16(1):82. DOI: 10.1186/s13045-023-01471-z.
[10] Devos T, Selleslag D, Granacher N,et al. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis[J]. Hematology, 2022, 27(1):23-31. DOI: 10.1080/16078454.2021.2009645.
[11] Saeed I, McLornan D, Harrison CN. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice[J]. Expert Rev Hematol, 2017, 10(7):617-625. DOI: 10.1080/17474086.2017.1337507.
[12] 杨志瑞,朱海燕. 芦可替尼治疗骨髓增殖性肿瘤安全性和有效性的Meta分析[J]. 中国实验血液学杂志,2018,26(2):493-501. DOI:10.7534/j.issn.1009-2137.2018.02.032.
|